Roche Gets FDA Approval for Multiple-Sclerosis Treatment
By Connor Hart
Roche Holding's Genentech unit said the Food and Drug Administration approved its twice-yearly, subcutaneous injection treatment for patients with two types of multiple sclerosis.
The treatment, called Ocrevus Zunovo, was approved as a biannual, approximately 10-minute, under-the-skin injection for patients with relapsing multiple sclerosis and primary progressive multiple sclerosis. Administered by a healthcare practitioner, the treatment contains drug-delivery technology developed by San Diego biopharmaceutical company Halozyme.
The approval is based on data from a phase 3 trial that showed no clinically significant difference in the levels of Ocrevus in patients' blood from the intravenous formulation, as well as a comparable safety and efficacy profile.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
September 13, 2024 14:46 ET (18:46 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
Undervalued by 25% and Yielding 5%, This Stock Is a Buy
-
Can AI Predict Future Stock Returns?
-
The Best Energy Stocks to Buy Now
-
10 Undervalued Wide-Moat Stocks
-
Obesity Drugs: Can New Firms Take Market Share From Eli Lilly and Novo Nordisk?
-
New 4-Star Stocks
-
Intel Fair Value Left Unchanged Despite Qualcomm Takeover Talk
United States